Revelation Biosciences Inc - Asset Resilience Ratio
Revelation Biosciences Inc (REVB) has an Asset Resilience Ratio of 0.34% as of September 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read REVB total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2020)
This chart shows how Revelation Biosciences Inc's Asset Resilience Ratio has changed over time. See REVB net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Revelation Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Revelation Biosciences Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.75K | 0.34% |
| Total Liquid Assets | $19.75K | 0.34% |
Asset Resilience Insights
- Limited Liquidity: Revelation Biosciences Inc maintains only 0.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Revelation Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Revelation Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Revelation Biosciences Inc (2016–2020)
The table below shows the annual Asset Resilience Ratio data for Revelation Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 11.37% | $525.29K | $4.62 Million | +3.73pp |
| 2018-12-31 | 7.64% | $187.56 Million | $2.46 Billion | -0.14pp |
| 2017-12-31 | 7.78% | $163.23 Million | $2.10 Billion | +0.41pp |
| 2016-12-31 | 7.37% | $139.61 Million | $1.89 Billion | -- |
About Revelation Biosciences Inc
Revelation Biosciences, Inc. operates as a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treat… Read more